Tradestie Institutional Equity Comparison Engine

BCAX vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while BCAX counters with relative strength in Growth & Margin. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BCAX N/M vs ZBIO N/M Fwd P/E
Growth & Margin Winner BCAX
Op Margin 0.0% vs -2747.5% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner ZBIO
1Y -31.6% vs -21.7% ยท 52W Pos 8% vs 46%
Options & Structure Winner ZBIO
BREAKDOWN (23rd %ile IV) vs CONSOLIDATION (13th %ile IV)
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BCAX -31.63% ZBIO -21.68% Spread: +9.95 pp (ZBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BCAX TTM Op. Margin: 0.0% ZBIO TTM Op. Margin: -2747.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs ZBIO. Trailing 12-month operating profitability (BCAX 0.0% vs ZBIO -2747.5%) and valuation multiples (BCAX N/M vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BCAX (4) vs ZBIO (3)
Institutional Metric BCAX ZBIO Criterion Row Winner
Market Capitalization Scale $665.2M $1.9B Larger Scale ZBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth BCAX
Operating Margin (TTM) Profitability 0.0% -2747.5% Higher Margin BCAX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -54.2% -265.1% Higher ROE BCAX
52-Week Range Position Momentum 8% ($8โ€“$31) 46% ($14โ€“$45) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 184% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 52.1 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite BCAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BCAX vs ZBIO Buy Guide
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BCAX nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.